Congratulations to Gilead’s Tomas Cihlar who received the 2025 Warren Alpert Foundation Prize for his scientific leadership in the development of a novel HIV medication that has the potential to change the landscape in HIV prevention and treatment. pic.x.com/awblsm27Fp
Posted on X
Gilead Sciences
GileadSciences
#InTheNews: Earlier today, we received FDA approval for our #HIV prevention medication. Read more on this milestone moment in our mission to help end the HIV epidemic: gilead.inc/4eaEiUO pic.x.com/PJeUDLm1H0
Posted on X
UNAIDS Global
UNAIDS
✍️@Guardian | Lenacapavir, twice-yearly HIV prevention injection could cost just $25 per patient a year, say researchers—yet may be priced at 1000x more.
This medicine could help end the HIV pandemic.
We urge @GileadSciences: Do the right thing. Make it affordable. Save lives.